PUBLISHER: DelveInsight | PRODUCT CODE: 1058081
PUBLISHER: DelveInsight | PRODUCT CODE: 1058081
DelveInsight's, 'Common Warts-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
The Common Warts market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM plus China Common Warts market size from 2019 to 2032. The Report also covers current Common Warts treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032
Common Warts Overview
Common warts, also known as verruca vulgaris, are caused by nonmalignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca vulgaris.
Most warts are harmless and will go away on their own within a few weeks or months. But they can be bothersome and unattractive, and some people feel ashamed. There are several different treatments that can make warts go away more quickly - but they do not always work. There are over 100 subtypes of the HPV virus, but only a few types can cause skin warts at selective anatomical sites. However, with skin contact, the HPV can be transferred to any body part. Common warts are associated with HPV types 2, 4 (most common), followed by types 1, 3, 27, 29, and 57.
Characteristics of the common wart include: round or oval-shaped; raised from the skin; firm, rough surface; variable size; and with a diameter within the range of 1 millimeter (mm) to 1 centimeter (cm).
Common Warts Diagnosis
The diagnosis of verruca vulgaris can be made after a small piece of the growth is removed in a procedure called a biopsy or after the entire growth is removed in a procedure called an excision. The tissue is then sent to a pathologist who examines it under the microscope.
Continued in the report…..
Common Warts Treatment
Treating warts is a therapeutic challenge for physicians. Although many different approaches exist, including observation and treatments combined for greater effectiveness, no single therapy has been proven effective at achieving complete remission in every patient. Verruca Vulgaris, the most common, manifests as hyperkeratotic papules, often on the hand.
The goals of treatment are to destroy the wart, stimulate an immune system response to fight the virus, or both. Treatment may take weeks or months. Even with treatment, warts tend to recur or spread. Doctors generally start with the least painful methods, especially when treating young children.
Continued in the report…..
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Common Warts, and gender-specific diagnosed prevalent cases of Common Warts in the 7MM plus China covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2019 to 2032.
Key Findings
The epidemiology segment also provides the Common Warts epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
The drug chapter segment of the Common Warts report encloses the detailed analysis of Common Warts mid-phase, and late-stage pipeline drugs. It also helps to understand the Common Warts clinical trial details, expressive pharmacological action, agreements and collaborations, and patent details of each included drug and the latest news and press releases.
Common Warts Emerging Drugs
Candin: Nielsen Bioscience
Nielsen Bioscience's Candin is one of the most promising molecule being developed to treat common warts. It is an intralesional administered therapy. The results of Phase II clinical trial involving common and non-common warts among adults were highly encouraging and are now advancing clinical research into the use of the antigen in common and non-common warts.
Products detail in the report…
VP-102: Verrica Pharmaceutical
VP-102 is being developed by Verrica Pharmaceutical as a controlled, shelf-stable drug-device combination product with a topical solution that contains cantharidin (0.7% w/v). In the Phase II trial, VP-102 Cantharidin showed efficacy in complete clearance of common warts from baseline to Day 84, as well as at follow-up visits. Due to the pandemic situation occurred in past years, in 2020, the clinical studies for common warts and plantar warts was putted on hold for the undefined time period.
Products detail in the report…
List to be continued in the report…
Different treatment methods are available for common warts at present, but none is universally fully effective. The majority of viral warts will spontaneously resolve on their own within 2 years. However, recurrence is very common.
Salicylic acid is used as a stronger peeling medicine to treat common warts. Prescription-strength wart medications with salicylic acid work by removing layers of a wart a little bit at a time. Studies show that salicylic acid is more effective when combined with freezing.
Other treatment approach can be followed is Imiquimod, (brand name Aldara). It is popular to treat genital and anal warts, but off-label, it is also widely used to treat common warts. Imiquimod cream does not cure warts, and new warts may appear during treatment. Another topical treatment to consider is silver nitrate, a chemical cautery performed by a stick pencil applicator associated with potassium nitrate in various concentrations. This treatment is mainly used in the UK where it is sold OTC. In the US, the FDA requires a prescription for 95% silver nitrate. Another topical agent is glutaraldehyde, available as a 10% solution in aqueous ethanol or in a gel formulation. Treatment with aminolevulinic acid (Levulan Kerastick) followed by phototoxicity is the mainstay of photodynamic therapy. Formaldehyde, another antiviral agent, can be applied once daily in a 0.7% gel or at a concentration of 3-10% in solution to treat common warts. Retinoids are vitamin A derivatives (retinol) with cellular and biologic actions that include regulation of epidermal proliferation and differentiation. Both topical and oral retinoids can be employed to treat warts via inhibition of HPV replication.
According to DelveInsight, the Common Warts treatment paradigm in the 7MM plus China is expected to change during the forecasted period 2022-2032.
Key Findings
This section provides the total Common Warts market size and; market size by therapies in the United States.
The total Common Warts market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Common Warts market size and market size by therapies in Japan are provided.
The total Common Warts market size and market size by therapies in China are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched in the market during the study period 2019-2032. The analysis covers Common Warts market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Common Warts Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Common Warts emerging therapies.
Reimbursement Scenario in Common Warts
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Common Warts market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Key Questions
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: